Abstract: The present invention relates to a peptide SSTP1 that modulates IL6 pathway to induce apoptosis in cells where there is overexpression of IL6R? (Interleukin 6 Receptor). This is achieved by inhibiting IL6/JAK/STAT pathway and/or by activating JNK/AP1 signal transduction pathway. The sensitivity of the cancer cells to SSTP1 was proportional to IL6R? levels. Further, SSTP1 kills triple negative breast cancer cells, MDA-MB-231, at a concentration that cause neither hemolysis nor cell death to blood cells. The peptide of the present invention utilizes the elements of IL6 pathway and induces apoptosis in cancer cells. SSTP1 functions by activation of JNK/AP1 pathway with concomitant inhibition of STATs, offering a new therapeutic strategy to treat cancer cells that overexpress IL6R?.

Abstract: The present invention includes Uttroside B compositions and method for the treatment of hepatocellular carcinoma. Chemotherapeutic options for liver cancer are limited and the prognosis of HCC patients remains dismal. Sorafenib, is the only drug currently available for the treatment of hepatocellular carcinoma.

Abstract: Antiviral polypeptides and methods of use are provided herein. In particular, these polypeptides can comprise the Yodha amino acid sequence, variants, derivatives, or truncated versions thereof. In certain embodiments, this disclosure relates to uses of the peptides, nucleic acid molecules, and compositions disclosed herein to treat or prevent a viral infection.

Abstract: The present invention includes Uttroside B compositions and method for the treatment of hepatocellular carcinoma. Chemotherapeutic options for liver cancer are limited and the prognosis of HCC patients remains dismal. Sorafenib, is the only drug currently available for the treatment of hepatocellular carcinoma.

Abstract: Antiviral polypeptides and methods of use are provided herein. In particular, these polypeptides can comprise the Yodha amino acid sequence, variants, derivatives, or truncated versions thereof. In certain embodiments, this disclosure relates to uses of the peptides, nucleic acid molecules, and compositions disclosed herein to treat or prevent a viral infection.

Abstract: Antiviral polypeptides and methods of use are provided herein. In particular, these polypeptides can comprise the Yodha amino acid sequence, variants, derivatives, or truncated versions thereof. In certain embodiments, this disclosure relates to uses of the peptides and compositions disclosed herein to treat or prevent a viral infection.

Abstract: This document provides methods and materials for identifying individuals with protein tyrosine kinase associated disorders for responsiveness to a kinase inhibitor (e.g., imatinib or nilotinib). For example, methods and materials for using a chemi-immunochromatographic lateral flow strip for detection of BCR-ABL and drug resistance are provided.

Abstract: Antiviral polypeptides and methods of use are provided herein. In particular, these polypeptides can comprise the Yodha amino acid sequence, variants, derivatives, or truncated versions thereof. In certain embodiments, this disclosure relates to uses of the peptides and compositions disclosed herein to treat or prevent a viral infection.

Abstract: This invention relates to a simple end point assay for detection of transient intracellular Ca2+ with broad applicability to many Ca2+ channel proteins comprising, Generation of expression constructs for the fusion proteins having the Ca2+/calmodulin dependent protein kinase II (CaMKII) phosphorylation sites of NR2A or NR2B subunits of N-methyl-D-aspartate receptor (NMDAR) or the voltage gated potassium channel of Drosophila (Eag) or any protein sequence which binds to the T-site of CaMKII similar to NR2B, conjugated to mitochondrial localizing signal sequence, or mutants of these sequences as described herein. Generation of mammalian expression constructs of ?-CaMKll as a chimera with green fluorescent protein (GFP-?-CaMKII) or its mutants as described herein.

Abstract: This invention relates to a simple end point assay for detection of transient intracellular Ca2+ with broad applicability to many Ca2+ channel proteins comprising, Generation of expression constructs for the fusion proteins having the Ca2+/calmodulin dependent protein kinase II (CaMKII) phosphorylation sites of NR2A or NR2B subunits of N-methyl-D-aspartate receptor (NMDAR) or the voltage gated potassium channel of Drosophila (Eag) or any protein sequence which binds to the T-site of CaMKII similar to NR2B, conjugated to mitochondrial localizing signal sequence, or mutants of these sequences as described herein. Generation of mammalian expression constructs of ?-CaMKll as a chimera with green fluorescent protein (GFP-?-CaMKII) or its mutants as described herein.

Abstract: This invention relates to a simple end point assay for detection of transient intracellular Ca2+ with broad applicability to many Ca2+channel proteins comprising, Generation of expression constructs for the fusion proteins having the Ca2+/calmodulin dependent protein kinase II (CaMKII) phosphorylation sites of NR2A or NR2B subunits of N-methyl-D-aspartate receptor (NMDAR) or the voltage gated potassium channel of Drosophila (Eag) or any protein sequence which binds to the T-site of CaMKII similar to NR2B, conjugated to mitochondrial localizing signal sequence, or mutants of these sequences as described herein. Generation of mammalian expression constructs of ?-CaMKll as a chimera with green fluorescent protein (GFP-?-CaMKII) or its mutants as described herein.

Abstract: A synthetic diaminoketothiazole, its process of preparation and its use as a microtubule inhibitor, a probe for tubulin-microtubule system and a cytotoxic agent. Diaminoketothiazole of the formula (I) wherein Ar is 4-OMe-C6H5, Ar? is C6H5.

Abstract: A synthetic diaminoketothiazole, its process of preparation and its use as a microtubule inhibitor, a probe for tubulin-microtubule system and a cytotoxic agent. Diaminoketothiazole of the formula (I) wherein Ar is 4-OMe-C6H5, Ar? is C6H5.

Abstract: A synthetic diaminoketothiazole, its process of preparation and its use as a microtubule inhibitor, a probe for tubulin-microtubule system and a cytotoxic agent. Diaminoketothiazole of the formula (I) wherein Ar is 4-OMe-C6H5, Ar? is C6H5.

Abstract: A novel polymer support for solid phase peptide synthesis comprising polystyrene backbone and propoxylate function of hexanedioldiacrylate crosslinks having optimum hydrophilic/hydrophobic balance and a process of preparation thereof.

Abstract: A novel polymer support for solid phase peptide synthesis comprising polystyrene backbone and propoxylate function of hexanedioldiacrylate crosslinks having optimum hydrophilic/hydrophobic balance and a process of preparation thereof.